Janssen to Highlight Depth of Solid Tumour Portfolio with Multiple Data Presentations at ESMO 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology (ESMO) 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain. Among Janssen’s 12 accepted abstracts is an oral presentation reporting overall survival from the Phase 3 SPARTAN study investigating the use of apalutamide in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the Phase 3 TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrating maintenance of overall health-related quality of life with apalutamide; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD).
“We are delighted to share key data from our solid tumour portfolio at this year’s ESMO Congress, including new findings for apalutamide and niraparib in the treatment of prostate cancer,” said Dr Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A.. “We continue to pursue areas of oncology where there is the greatest unmet need, and the data being presented in Barcelona reflects our ongoing passion and commitment to improving patient outcomes.”
Company-sponsored abstracts to be presented at the meeting include:
|
Abstract No. |
Title |
Date/Time |
|
Apalutamide |
||
|
Oral Presentation |
||
|
Abstract #843O |
Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study |
Friday 27th September 14:00 - 14:15 CET |
|
Poster Presentations |
||
|
Abstract #851PD |
Patient-Reported Outcomes (PROs) From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
Sunday 29th September 09:20 CET |
|
Abstract #883P |
Androgen Receptor Aberrations in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated with Apalutamide Plus Androgen Deprivation Therapy in TITAN |
Monday 30th September 12:00 – 13:00 CET |
|
Abstract #900TiP |
A Phase 2 randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy |
Monday 30th September 12:00 – 13:00CET |
|
Abiraterone acetate |
||
|
Poster Presentation |
||
|
Abstract #95P |
Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study |
Monday 30th September 12:00 – 13:00 CET |
|
Niraparib |
||
|
Poster Presentations |
||
|
Abstract #LBA50
|
Pre-specified interim analysis of GALAHAD: A Phase 2 study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects |
Sunday, 29th September 08:30 CET |
|
Abstract #897TiP |
A Phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) |
Monday 30th September 12:00 – 13:00 CET |
|
Abstract #1412P |
Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib |
Monday 30th September 12:00 – 13:00 CET |
|
Erdafitinib |
||
|
Poster Presentations |
||
|
Abstract #925P |
Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients with metastatic urothelial carcinoma |
Monday 30th September 12:00 CET |
|
Abstract #926P |
Erdafitinib versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison |
Monday 30th September 30 12:00 CET |
|
Abstract #932P |
Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Antitumor Activity Among Patients with Advanced Urothelial Carcinoma |
Monday 30th September 12:00 CET |
|
Solid Tumor Portfolio |
||
|
Poster Presentation |
||
|
Abstract #488P |
Correlation of Progression Free Survival-2 and Overall Survival in Solid Tumors |
Saturday 28th September 12:00 CET |
About ERLEADA® (apalutamide)
ERLEADA® (apalutamide) is an androgen receptor (AR) inhibitor indicated for use in Europe for the treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).1 In the U.S. apalutamide is indicated for the treatment of nmCRPC.2
About ZYTIGA® (abiraterone acetate)
ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated in Europe and the U.S. for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC).3,4
About BALVERSATM (erdafitinib)
BALVERSA™ (erdafitinib) is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor that is currently being studied for the treatment of patients with advanced or metastatic urothelial cancer.5 In the U.S. it is indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.6
About niraparib
Niraparib is an orally-administered selective poly ADP ribose polymerase (PARP) inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer.7 In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer.8 In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.9 Niraparib is currently marketed by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer.10
# # #
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding potential benefits and further benefits of ERLEADA® (apalutamide), ZYTIGA® (abiraterone acetate), BALVERSATM (erdafitinib) and niraparib. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1 European Medicines Agency. ERLEADA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf. Last accessed September 2019.
2 ERLEADA product information Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf. Last accessed September 2019.
3 European Medicines Agency. ZYTIGA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga. Last accessed September 2019.
4 U.S. Food and Drug Administration. ZYTIGA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202379s024lbl.pdf. Last accessed September 2019.
5 U.S. National Library of Medicine. A study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor (FGFR) gene aberrations. Available at: https://clinicaltrials.gov/ct2/show/NCT03390504. Last accessed September 2019.
6 U.S. Food and Drug Administration. BALVERSA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Last accessed September 2019.
7 U.S. National Library of Medicine. A study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (QUEST). Available at: https://clinicaltrials.gov/ct2/show/NCT03431350. Last accessed September 2019.
8 CISION. Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer. Available at: https://www.prnewswire.com/news-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-tesaro-inc-for-niraparib-in-prostate-cancer-300246733.html. Last accessed September 2019
9 U.S. Food and Drug Administration. Niraparib Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf. Last accessed September 2019.
10 Zejula® niraparib. Summary of Product Characteristics. Tesaro UK Limited. Available at: https://www.medicines.org.uk/emc/product/8828/smpc. Last accessed September 2019.
Date of prep: September 2019
Job number: EM-18161
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190918005368/en/
Contact information
Media Enquiries:
Laura Coughlan
Phone: +353 87 147 9356
Noah Reymond
Phone: +31 621 385 718
Investor Relations:
Christopher DelOrefice
Phone: +1 732 524 2955
Lesley Fishman
Phone: +1 732 524 3922
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Announces the Jury for the First AI Music Contest: Finalists Will Perform Live on Stage at Kappa FuturFestival in Turin23.5.2025 11:05:00 EEST | Press release
Reply, an international group specialized in the creation of new business models enabled by Artificial Intelligence and driven by a strong culture of innovation, is expanding its creative experimentation initiatives this year with the launch of the AI Music Contest. Organised in collaboration with Kappa FuturFestival, one of Europe’s leading electronic music festivals, the competition is open to creatives and innovators who use AI technologies to explore new forms of integration between sound and visuals. It aims to enhance the expressive potential of artificial intelligence in live performances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250523250887/en/ The jury members include prominent figures such as Seth Troxler and DJ Tennis, who are renowned DJs and producers known for their pioneering use of AI in live performances. Also on the panel is Albertino, a DJ, radio host and the artistic director of Radio m2o. Alongsid
Kioxia Holdings Corporation Wins IPO of the Year Award in the Equity Category at the DealWatch Awards 202423.5.2025 10:00:00 EEST | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced that it had won the IPO of the Year award in the Equity category at the DealWatch Awards 2024, organized by DealWatch, the most authoritative source of real-time intelligence for deal activity within Japan's capital markets. The award was presented at a ceremony held on May 20. The DealWatch Awards recognize outstanding issuers of bonds or equities in the Japanese capital market, as well as Japanese issuers who have conducted offerings overseas, and the securities firms that manage these transactions. The awards for 2024 comprised six categories: Overall, Bonds, Local Government Bonds, Cross-Border Bonds, Sustainable Finance, and Equity. Selection is based on criteria such as the appropriateness of pricing in the issuance market, price formation after transition to the trading market, contribution to the development of capital markets, and innovative efforts, with the awards designed to promot
Generix Named in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS) for the Seventh Consecutive Year23.5.2025 10:00:00 EEST | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces it has been recognized by Gartner in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS). This is the seventh consecutive year that Generix has been recognized for its portfolio of WMS Solutions. Designed to scale as supply chain operations grow from simple to complex flows, Generix WMS and Solochain WMS are currently in more than 2,000 warehouses globally. “We are honored to be recognized in the Gartner® Magic Quadrant™ WMS for the seventh consecutive year. Generix continues its commitment to providing WMS for every warehousing need at a global scale. With our two recognized WMS solutions, Generix WMS and Solochain WMS, we continue to innovate to better serve customer needs with the introduction of industry game-changing AI use-cases such as resource planning and computer vision,” said Si-Mohamed Sa
NuORDER by Lightspeed and Mandatory Renew Partnership to Power Hybrid Commerce at the Third Edition of the Copenhagen Event23.5.2025 10:00:00 EEST | Press release
Mandatory and NuORDER by Lightspeed, the industry’s leading B2B commerce platform, are joining forces for the third consecutive time to power the digital extension of Mandatory’s in-person trade event, taking place August 5–7 in Copenhagen. This renewed partnership reflects the continued momentum behind hybrid commerce—where physical and digital trade intersect to create smarter, more flexible buying experiences. As the Nordic fashion ecosystem expands with energy and innovation, Mandatory has become a magnet for trendsetting brands and forward-looking retailers. On NuORDER’s wholesale platform, buyer activity from Nordic-region retailers surged by 39.4% year over year in Q1 2025 (January to March). "Retailers in the Nordic region have been quick to adopt digital tools to enhance the efficiency of their buying processes. The increase in buyer activity on the NuORDER platform early this year clearly indicates a growing market demand and a renewed engagement within the industry," said Ch
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom